Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers
Posted inCardiology Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers

A multicenter double-blind RCT (n=160) found that 12 weeks of simvastatin (40 mg) added to escitalopram did not improve depressive symptoms versus placebo, although LDL, total cholesterol, and CRP were reduced.
The Effect of Chitosan Supplementation on Liver Function, Hepatic Steatosis Predictors, and Metabolic Indicators in Adults with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

The Effect of Chitosan Supplementation on Liver Function, Hepatic Steatosis Predictors, and Metabolic Indicators in Adults with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

This clinical trial evaluates chitosan supplementation's impact on liver health and metabolic markers in adults with NAFLD, showing potential benefits alongside a low-calorie diet.
Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial

A 12-week hypocaloric Mediterranean diet with early time-restricted feeding improved glycaemic control and cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) compared to unrestricted timing or late time-restricted feeding.